https://bioutah.org/fda-approves-roflumilast-cream-0-3-for-plaque-psoriasis-down-to-age-2/2026-07-01T20:35:05ZBioUtahenFDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis Down to Age 22026-07-01T20:34:36ZBloghttps://bioutah.org/arcutis-launches-new-virtual-health-platform-supporting-access-to-care-for-individuals-living-with-chronic-inflammatory-skin-diseases-including-approved-zoryve-roflumilast-indications/2026-07-01T20:33:18ZBioUtahenArcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications2026-07-01T20:31:20ZBloghttps://bioutah.org/early-phase-data-support-novel-contrast-agent/2026-07-01T20:20:05ZBioUtahenEarly-Phase Data Support Novel Contrast Agent2026-07-01T20:19:20ZBloghttps://bioutah.org/biomerieux-seeks-fda-authorization-for-point-of-care-vaginitis-test/2026-07-01T20:17:42ZBioUtahenbioMérieux Seeks FDA Authorization for Point-of-Care Vaginitis Test2026-07-01T20:17:42ZBloghttps://bioutah.org/nusano-completes-major-milestone-toward-commercial-radioisotope-production/2026-07-01T20:16:08ZBioUtahenNUSANO COMPLETES MAJOR MILESTONE TOWARD COMMERCIAL RADIOISOTOPE PRODUCTION2026-07-01T20:16:08ZBlog